Renal transplantation, past, present and future

Journal of Nephrology

Volumn 12, Issue SUPPL. 2, 1999, Pages

  Ponticelli, Claudio ^a   Tarantino, Antonio ^a   Vegeto, Antonio ^b  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^b IRCCS   (Italy)

Author keywords

Cyclosporine; Immunosuppression; Rejection; Renal transplantation

Indexed keywords

CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT;

ACUTE DISEASE; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; KIDNEY TRANSPLANTATION; REVIEW;

ACUTE DISEASE; CYCLOSPORINE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION;

EID: 0033155216     PISSN: 11218428     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (61)

1. Murray JE, Merrill JP, HarrisonJU. Kidney transplantation between seven pairs of identical twins. Ann Surg 1958; 148:343-8.
2. Hamburger J, Crosnier J, DormontJ, BachJF. La transplantation rénale. Paris: Flammarion 1971; 17-20.
3. Calne RY. The rejection of renal homografts. Inhibition in dogs by 6-MP. Lancet 1960; i: 417-20.
4. DaussetJ. Iso-leuco-anticorps. Acta Haematol 1958; 20: 156-62.
5. Wertheimer P, Jouvet M, Descotes J. A propos du diagnostic de la mort du système nerveux. Presse Med 1959; 67: 87-8.
6. Advisory Committee of the Transplant Registry: Seventh report of the human kidney transplant registry. Transplantation 1969; 8: 721-8.
7. Bell PRF, Briggs JD, Colman KG et al. Reversal of acute clinical experimental organ rejection using large doses of intravenous prednisolone. Lancet 1971; i: 876-80.
8. Gray D, Shepherd H, Daar A et al. Oral versus intravenous high dose steroid treatment of renal allograft rejection. Lancet 1978; i: 117-20.
9. Me Geown MG, Douglas JF, Brown WA et al. Advantages of low dose steroid from the day after renal transplantation. Transplantation 1980; 29: 287-9.
10. Ponticelli G, De Vecchi A, Tarantino A et al. A search for optimizing corticosteroid administration to renal transplant patients. Kidney Int 1983; 23(suppl 14): S85-9.
11. Morris PJ, Chan L, Franch ME, Thing A. Low dose oral prednisone in renal transplantation. Lancet 1982; 1: 525-7.
12. Opelz G, Terasaki PI. Improvement of kidney graft survival with increased number of blood transfusions. N EnglJ Med 1978; 299: 799-803.
13. Kung PC, Goldstein G, Reinhertz EL et al. Monoclonal antibodies defining distinctive human T-cell surface antigen. Science 1979; 206: 347-9.
14. Ortho Multicenter Study Group. A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants. N EnglJ Med 1985; 313: 337-42.
15. Schroeder TJ, Neiss MA, Smith RD et al. The efficacy of OKT3 in vascular rejection. Transplantation 1991; 51: 312-5.
16. Hardy M, Nowygrod R, Elberg A et al. Use of ATG in the treatment of steroid-resistant rejection. Transplantation 1980; 29: 162-4.
17. Matas AJ, Tellis VA, Quinn T et al. Treatment of renal transplant rejection episodes in patients receiving prednisone and azathioprine. Transplantation 1985; 40: 35-9.
18. Borel JF. Comparative study of in vitro and in vivo drug effects on cell mediated cytotoxicity. Immunology 1976; 31: 631-41.
19. European Multicenter Trial Group. Cyclosporin in cadaveric renal transplantation: one-year follow-up in a multicentre trial. Lancet 1983; ii: 986-9.
20. Canadian Multicenter Transplant Study Group. A randomized clinical trial of cyclosporine in cadaveric renal transplantation. N EnglJ Med 1983; 309: 809-15.
21. Mihatsch MJ, Ryffel B, Gudat F. The differential diagnosis between rejection and cyclosporine toxicity. Kidney Int 1995; 48(suppl52):S63-9.
22. Remuzzi G, Perico N. Cyclosporine-induced renal dysfunction in experimental animals and humans. Kidney Int 1995; 48(suppl52):S70-4.
23. Bennett WM, De Maltas A, Meyer MM, Andoh T, Barry JM. Chronic cyclosporine nephropathy: the Achille's heel of immunosuppressive tlierapy. Kidney Int 1996; 50: 1089-100.
24. BurkeJF, PirschJD, Ramos EL, Salomon DR, Stabley DM, Van Buren DH. Long-term efficacy and safety of cyclosporine in renal transplant recipients. N EnglJ Med 1994; 331: 358-63.
25. Ponticclli G, Civati G, Tarantino A et al. Randomized study with cyclosporine in kidney transplantation: 10-year follow-up J Am Soc Nephrol 1996; 7: 792-7.
26. Mourad G, Vela C, Ribstein J, Mimran A. Long-term improvement in renal function after cyclosporine reduction in renal transplant recipients with histologically proven chronic cyclosporine nephropathy. Transplantation 1998; 65: 661-6.
27. Ponticelli C, Tarantino A, Segoloni G et al. A randomized study comparing three cyclosporine-based regimens in cadaveric renal transplantation. J Am Soc Nephrol 1997; 8: 638-46.
28. Tarantino A, Segoloni G, Cambi V et al. A randomized study comparing three cyclosporine- based regimens in cadaveric renal transplantation: results at 7 years. Transplant Proc 1998; 30: 1729-31.
29. Szczech LA, Berlin JA, Aradhye S, Grossman RA, Feldman HI. Effect of antilymphocyte induction therapy on renal allograft survival; a meta-analysi's.J Am Soc Nephrol 1997; 8: 1771-7.
30. PirschJD, Miller J, Deierhoi MH, Vincenti F, Filo RS. A comparison of Tacrolimus (FK 506) and cyclosporine for immunosuppression after cadaveric renal transplantation. Transplantation 1997; 63: 977-83.
31. Mayer AD, Dimitreski J, Squifflet JP et al. Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection: a report of the European Tacrolimus Multicenter Renal Study Group. Transplantation 1997; 64: 436-42.
32. Jordan ML, Shapiro R, Vivas ÇA et al. FK506 "rescue" for resistant rejection of renal allografts under primary cyclosporine immunosuppression. Transplantation 1994; 57: 860-5.
33. Woodle ES, Cronin D, Newell KA et al. Tacrolimus therapy for refractory acute renal allograft rejection: definition of the histologie response by protocol biopsies. Transplantation 1996; 62: 906-10.
34. LodgeJPA, Pollard SG. Neoral vs Sandimmun: Interim analy-
35. sis of a randomized trial of efficacy and safety in preventing acute rejection in new renal transplant recipients. Transplant Proc 1997; 29: 272.
36. Halloran P, Mathew TH, Tomlanovich S, Grotli C, Hooftman L, Barker C. Mycophenolate mofetil in renal allograft recipients. Transplantation 1997; 63: 39-47.
37. Mathew TH. A blinded, long-term, randomized nnlticenter study of mycophenolate mofetil in cadaveric renal transplantation; results at three years. Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. Transplantation 1998; 65: 14504.
38. Mycophenolate Mofetil Renal Refractory Rejection Study Group. Mycophenolate mofetil for the treatment of refractory, acute cellular renal transplant rejection. Transplantation 1996; 61: 722-9.
39. Vincenti F, Kirkman R, Light S, et al. Interleukin-2 receptor blockade with daclizumab to prevent acute rejection in renal transplantation. N EnglJ Med 1998; 338: 161-5.
40. Nashan B, Moore R, Amlot P, Schmidt AG, Abeywickrama K, SoulillouJP. Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. Lancet 1997; ii: 1193-8.
41. Kalian BD, ChangJY, Sehgal SN. Preclinical evaluation of a new potent immunosuppressive agent: Rapamycin. Transplantation 1991; 52: 185-791.
42. Kalian BD. Rapamycin: Personal algorithms for use based on 250 treated renal allograft recipients. Transplant Proc 1998; 30: 2185-8.
43. Diloseph JF, Mihatsch MJ, Sehgal SN. Renal effects of rapamycin in the spontaneously hypertensive rat. Transplant Int 1994; 7: 83-8.
44. Schuurman HJ, Schuler W, Ringers J, Jonker M. The macroline SDZ RAD is efficacious in a nonhuman primate model of allotransplantation. Transplant Proc 1998; 30: 2198-9.
45. Kalian BD. The three fates of immunosuppression in the next millenium: selectivity, synergy, and specificity. Transplant Int 1996; 9: 527-34.
46. Yanagawa Y, Sugahara K, Kataoka K et al. FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homings in rats. II. FTY720 prolongs skin allograft survival by decreasing T cell infiltration into grafts but not cytokine production in vivo.] Immunol 1998; 160: 5493-9.
47. Kahan BD. FTY720. a new immunosuppressive agent with novel mechanism(s) of action. Transplant Proc 1998; 30: 2210-3.
48. Dustin ML, Springer TA. Role of lymphocyte adhesion receptor in transient interactions and cell locomotion. Annu Rev Immunol 1991; 9: 27-66.
49. GloverJM, LeedsJM, Mant TGK et al. Phase I safety and pharmacokinetic profile of an intercellular adhesion molecule-1 antisense oligodeoxynucleotide (ISIS 2302). J Pharmacol Exp Ther 1997; 282: 1173-80.
50. Sachs DH. Transplantation tolerance. Transplant Proc 1998; 30: 1627-9.
51. Knechtle SJ, Vargo D, Fetchner J et al. FN18-CRM9 immunotoxin promotes tolerance in primate renal allografts. Transplantation 1997; 63:1-6.
52. Morris PJ. Progress in the induction of tolerance to allografts. Transplant Proc 1998; 30: 2427-9.
53. Larscn CP, Elwood ET, Alexander DZ et al. Long-term acceptance of skin and cardiac allograft after blocking CD40 and CD28 pathways. Nature 1996; 381: 434-8.
54. Posselt AM, Barker CF, Tomazewski JE et al. Induction of donor-specific unresponsiveness by intrathymic islet transplantation. Science 1990; 249: 1293-5.
55. CeckaJM. Results of 1000 recent living unrelated donor transplants in the United States. XVII World Congress of Transplantaüon. Montreal July. Book of Abstracts 1998; 12-17: 102-370.
56. Daemen JHC, Oomeii APA, Kelders WPA, Koostra G. The potential pool of non-heart-beating donors. Clin Transplant 1997; 11: 149-54.
57. LloverasJ. Elderly and other suboptimal renal grafts and transplant outcomes. Transplant Proc 1998; 30: 2272-3.
58. Weight C, Cohen B, Beasley C et al. Donor action: a systematic approach to organ donation. Transplant Proc 1998; 30:2253-4.
59. Zaidi A, Bhatti F, Schmoeckel M et al. Kidneys from DAF transgenic pigs are physiologically compatible with primates. Transplant Proc 1998; 30: 2465-6.
60. Cooper DKC. The safety of xenotransplantation. Transplant Proc 1998; 30: 2461-2.
61. Martin U, Steinhoff G, Kiessig V, et al. Porcine endogenous retrovirus (PERV) was not transmitted from transplanted porcine endothelial cells to baboons in vivo. Transplant Int 1998; 11: 247-51.